US · BNR
Burning Rock Biotech Limited
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Guangzhou 510005
- Website
- brbiotech.com
Price · as of 2024-12-31
$17.10
Market cap 27.81M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $1.10 | -93.57% |
| Intrinsic Value(DCF) | $2.48 | -85.49% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $270.90 | $123.35 | $228.17 | $9.10 | $0.00 |
| 2021 | $74.20 | $30.18 | $7.76 | $0.00 | $0.00 |
| 2022 | $28.90 | $14.22 | $0.00 | $0.00 | $0.00 |
| 2023 | $8.02 | $8.92 | $0.00 | $0.00 | $0.00 |
| 2024 | $5.66 | $7.75 | $0.31 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Burning Rock Biotech Limited's (BNR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $1.10
- Current price
- $17.10
- AI upside
- -93.57%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.48
-85.49% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BNR | Burning Rock Biotech Limi… | $17.10 | 27.81M | -55% | -85% | — | — | -1.20 | 0.72 | 0.81 | 0.19 | — | 0.72 | 70.26% | -69.32% | -67.20% | -51.38% | -256.37% | -36.01% | 0.09 | — | 2.92 | 2.60 | 1.73 | -4726.00% | -402.00% | -6295.00% | -23.64% | -0.35 | -70.44% | 0.00% | 0.00% | 0.02% | 0.15 | 0.53 | -0.10 | -5.88 |
| ADVB | Advanced Biomed Inc. Comm… | $4.06 | 4.4M | — | — | — | — | -1690.19 | 0.05 | — | — | -7324.16 | 0.05 | 0.00% | — | — | -0.01% | 0.00% | 0.00% | 0.00 | — | 2.09 | 1.01 | — | 2308.00% | — | -9171.00% | -0.11% | 0.00 | -0.06% | 0.00% | 0.00% | 1690.13% | — | 14968.87 | — | -3.52 |
| AEMD | Aethlon Medical, Inc. | $2.01 | 1.53M | — | — | — | — | -0.31 | 0.80 | — | 0.06 | -0.40 | 0.80 | 0.00% | — | — | -245.88% | -1215.78% | -171.58% | 0.13 | -924.06 | 3.13 | 2.90 | 0.37 | 7654.00% | — | -2635.00% | -185.54% | -4.03 | -995.06% | 0.00% | 0.00% | 8.49% | 0.08 | 0.10 | — | -34.37 |
| ALUR | Allurion Technologies Inc… | $1.17 | 9.09M | +15,409% | -17% | — | +29,866% | -0.21 | -0.07 | 0.17 | -1.26 | — | -0.07 | 66.97% | -156.33% | -81.43% | 35.22% | 82.22% | -50.03% | -0.49 | -22.17 | 1.44 | 1.19 | -1.02 | -7987.00% | -3994.00% | -3457.00% | -785.83% | -2.24 | 70.29% | 0.00% | 0.00% | 0.00% | -0.56 | -0.65 | 0.87 | -13.22 |
| AYTU | Aytu BioPharma, Inc. | $2.57 | 20.82M | +791% | +627% | — | — | -1.04 | 0.74 | 0.21 | -1.31 | — | -0.61 | 69.04% | -11.79% | -20.43% | -58.10% | -44.62% | -11.16% | 1.21 | -2.11 | 1.26 | 0.98 | 1.72 | -2448.00% | 184.00% | 20082.00% | -36.55% | -0.03 | -29.45% | 0.00% | 0.00% | 31.33% | -0.78 | -1.18 | 0.09 | -3.20 |
| CODX | Co-Diagnostics, Inc. | $2.30 | 2.57M | +1,244% | +270% | — | +1,660% | -13.54 | 9.38 | 130.17 | -12.45 | -406.20 | 18.07 | 74.48% | -1023.75% | -961.37% | -53.65% | -140.21% | -47.25% | 0.04 | — | 4.41 | 4.08 | 0.02 | 333.00% | -4253.00% | 2754.00% | -5.87% | -3.99 | -104.61% | 0.00% | 0.00% | 0.00% | -12.03 | -16.12 | 123.12 | 29.30 |
| EKSO | Ekso Bionics Holdings, In… | $10.14 | 24.6M | +55% | -60% | — | +814% | -2.12 | 2.75 | 1.94 | -2.68 | -0.27 | 4.87 | 53.48% | -104.12% | -91.37% | -107.62% | -117.46% | -50.02% | 0.29 | -43.13 | 1.63 | 0.98 | -0.15 | 77679.00% | -2860.00% | 2131.00% | -48.31% | -1.37 | -105.67% | 0.91% | -1.90% | 0.91% | -1.97 | -2.19 | 2.05 | -18.15 |
| NVNO | enVVeno Medical Corporati… | $10.00 | 165.03K | — | — | — | — | -0.07 | 0.04 | — | 1.91 | — | 0.04 | 0.00% | — | — | -49.39% | -3781.90% | -46.63% | 0.03 | — | 20.88 | 20.60 | 0.03 | -3351.00% | — | -1067.00% | -1122.35% | -8.04 | -2678.57% | 0.00% | 0.00% | 0.00% | 1.70 | 2.41 | — | -5.04 |
| PMN | ProMIS Neurosciences, Inc… | $23.51 | 30.74M | — | — | — | — | 7.09 | 1.19 | — | 2.23 | — | 1.19 | 0.00% | — | — | 27.46% | 589.07% | 17.08% | 0.00 | -219.18 | 8.52 | 6.04 | -4.65 | -10775.00% | — | 15067.00% | -137.99% | -12.25 | 951.55% | 0.00% | 0.00% | 3.52% | -0.38 | -0.23 | — | -3.71 |
| PRPH | ProPhase Labs, Inc. | $0.15 | 710.55K | +15,560% | +1,020% | — | +135,988% | -1.62 | 10.90 | 11.84 | -3.22 | -0.97 | -10.50 | -2.22% | -570.59% | -788.24% | -174.58% | -79.42% | -63.85% | 3.34 | -11.53 | 0.95 | 0.65 | -0.74 | 16633.00% | -8475.00% | 2717.00% | -23.02% | -0.55 | -37.92% | 0.00% | 0.00% | 0.00% | -2.69 | -5.64 | 15.37 | -2.37 |
About Burning Rock Biotech Limited
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.
- CEO
- Yusheng Han
- Employees
- 674
- Beta
- 1.32
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.48 ÷ $17.10) − 1 = -85.49% (DCF, example).